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Supplementary table 1: Definitions of healthcare-associated infections for neonates, bloodstream infections and clinical sepsis – Paediatric 
data, standard protocol, ECDC point prevalence survey 2011-2012 
 
BSI: BLOODSTREAM INFECTION 
BSI: Laboratory-confirmed bloodstream infection  
One positive blood culture for a recognised pathogen 
or 
patient has at least one of the following signs or symptoms: fever (> 38 °C), chills, or hypotension 
and 
two positive blood cultures for a common skin contaminant (from two separate blood samples, usually 
within 48 hours) 
 
Skin contaminants: coagulase-negative staphylococci (including S. epidermidis), Micrococcus spp., 
Propionibacterium acnes, Bacillus spp., Corynebacterium spp. 
 
- Primary bloodstream infections include catheter-related BSI and BSI of unknown origin. 
- A CVC-associated bloodstream infection according to CDC/NHSN definitions (different from CVC-
related BSI) is a primary BSI with central vascular catheter use (even intermittent) in the 48 hours 
preceding the onset of the infection: therefore the presence of ‘the relevant device’ (central/peripheral 
vascular catheter) in the 48 hours before onset of infection is collected even in the absence of 
microbiological confirmation 
CRI: CATHETER-RELATED INFECTION 
CRI1-CVC: local CVC-related infection (no positive blood culture)  
Quantitative CVC culture ≥ 103 CFU/ml (1) or semi-quantitative CVC culture > 15 CFU 
and 
pus/inflammation at the insertion site or tunnel 
 
 
CRI1-PVC: local PVC-related infection (no positive blood culture) 
 
Quantitative PVC culture ≥ 103 CFU/ml or semi-quantitative PVC culture > 15 CFU 
and 
pus/inflammation at the insertion site or tunnel 
 
 
CRI2-CVC: General CVC-related infection (no positive blood culture) 
Quantitative CVC culture ≥ 103 CFU/ml or semi-quantitative CVC culture > 15 CFU 
and 
clinical signs improve within 48 hours after catheter removal 
 
 
CRI2-PVC: General PVC-related infection (no positive blood culture) 
Quantitative PVC culture ≥ 103 CFU/ml or semi-quantitative PVC culture > 15 CFU 
and 
clinical signs improve within 48 hours after catheter removal 
 
 
CRI3-CVC: microbiologically confirmed CVC-related bloodstream infection 
BSI occurring 48 hours before or after catheter removal 
and 
positive culture with the same microorganism of either: 
- quantitative CVC culture ≥ 103 CFU/ml or semi-quantitative CVC culture > 15 CFU 
- quantitative blood culture ratio CVC blood sample/peripheral blood sample > 5 (3) 
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- differential delay of positivity of blood cultures (4): CVC blood sample culture positive two hours or 
more before peripheral blood culture (blood samples drawn at the same time) 
- positive culture with the same microorganism from pus from insertion site 
 
CRI3-PVC: microbiologically confirmed PVC-related bloodstream infection 
BSI occurring 48 hours before or after catheter removal 
and 
positive culture with the same microorganism of either: 
- quantitative PVC culture ≥ 103 CFU/ml or semi-quantitative PVC culture > 15 CFU 
- positive culture with the same microorganism from pus from insertion site 
- Central vascular catheter colonisation should not be reported 
- A CRI3 (-CVC or -PVC) is also a bloodstream infection with source C-CVC or C-PVC respectively; 
however: when a CRI3 is reported, the BSI should not be reported in the point prevalence survey; 
microbiologically confirmed catheter-related BSI should be reported as CRI3 
SYS: SYSTEMIC INFECTIONS 
SYS-CSEP: clinical sepsis in adults and children  
Patient has at least one of the following criteria: 
- clinical signs or symptoms with no other recognised cause 
- fever (38 °C) 
- hypotension (systolic pressure < 90 mm) 
- or oliguria (20 cm3 (ml)/hour) 
and 
- blood culture not done or no organisms or antigen detected in blood 
and 
- no apparent infection at another site 
and 
- physician institutes treatment for sepsis 
- Do not use this code unless absolutely needed (last-resort definition) 
- For CSEP in neonates, use NEO-CSEP case definition (see below) 
 
NEO: SPECIFIC NEONATAL CASE DEFINITIONS 
NEO-CSEP: clinical sepsis in neonates  
All of the three following criteria: 
- supervising physician started appropriate antimicrobial therapy for sepsis for at least five days 
- no detection of pathogens in blood culture or not tested 
- no obvious infection at another site 
and 
two of the following criteria (without other apparent cause): 
- fever (> 38 °C) or temperature instability (frequent post-set of the incubator) or hypothermia (< 36.5°C) 
- tachycardia (> 200/min) or new /increased bradycardia (< 80/min) 
- capillary refilling time (CRT) > 2s 
- new or increased apnoea(s) (> 20s) 
- unexplained metabolic acidosis 
- new-onset hyperglycemia (> 140mg/dl) 
- another sign of sepsis (skin colour (only if the CRT is not used), laboratory signs (CRP, interleukin), 
increased oxygen requirement (intubation), unstable general condition of the patient, apathy) 
 
A one-time detection of coagulase-negative staphylococci (CNS) in blood cultures should not exclude the 
diagnosis of clinical sepsis. A clinical sepsis can also be diagnosed with a single positive blood culture with 
CNS, which is considered as a blood culture contamination, while other criteria of CNS bloodstream 
infection are not met and criteria of clinical sepsis have been met. 
 
NEO-LCBI: laboratory-confirmed BSI  
At least two of:  
- temperature > 38 °C or < 36.5 °C  or temperature instability  
- tachycardia or bradycardia, 
- apnoea 
- In order to be consistent with BSI reporting in adults (including secondary BSI), the criterion ‘the 
organism is not related to an infection at another site’ was removed from the Neo-KISS definition for the 
purposes of the ECDC PPS 
- Report the origin of the neonatal BSI in the field BSI origin 
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- extended capillary refilling time (CRT) 
- metabolic acidosis 
- hyperglycaemia 
- other sign of BSI such as apathy; 
and 
- a recognised pathogen other than coagulase-negative staphylococci (CNS) cultured from blood or 
cerebrospinal fluid (CSF; this is included because meningitis in this age group is usually 
haematogenous, so positive CSF can be regarded as evidence of BSI even if blood cultures are negative 
or were not taken) 
 
- If both the case definitions for NEO-LCBI and NEO-CNSB are matched, report NEO-LCBI 
 
NEO-CNSB: laboratory-confirmed BSI with coagulase-negative staphylococci (CNS) 
At least two of:  
- temperature > 38 °C or < 36.5 °C  or temperature instability  
- tachycardia or bradycardia, 
- apnoea 
- extended capillary refilling time (CRT) 
- metabolic acidosis 
- hyperglycaemia 
- other sign of BSI such as apathy; 
and 
- CNS is cultured from blood or catheter tip; 
and 
patient has one of:  
- C-reactive protein > 2.0 mg/dL 
- immature/total neutrophil ratio (I/T ratio) > 0.2  
- leukocytes < 5/nL 
- platelets <100/nL 
 
- Report the origin of the neonatal BSI in the field BSI origin 
- If both the case definitions for NEO-LCBI and NEO-CNSB are matched, report NEO-LCBI 
 
NEO-PNEU: pneumonia  
Respiratory compromise 
and 
new infiltrate, consolidation or pleural effusion on chest x-ray; 
and 
at least four of:  
- temperature > 38 °C or < 36.5 °C or temperature instability 
- tachycardia or bradycardia 
- tachypnoea or apnoea 
- dyspnoea  
- increased respiratory secretions 
- new onset of purulent sputum 
- isolation of a pathogen from respiratory secretions 
- C-reactive protein > 2.0 mg/dL 
- I/T ratio >0.2 
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NEO-NEC: necrotising enterocolitis  
Histopathological evidence of necrotising enterocolitis 
or  
at least one characteristic radiographic abnormality (pneumoperitoneum, pneumatosis intestinalis, 
unchanging ‘rigid’ loops of small bowel) 
and 
at least two of the following without other explanation: 
- vomiting 
- abdominal distention 
- prefeeding residuals 
- persistent microscopic or gross blood in stools 
 
 
BSI = bloodstream infection; CFU = colony forming unit; CNSB = coagulase negative staphylococcus bacteraemia; CDC = US Center for Disease Control and Prevention; CNS = 
coagulase negative staphylococci; CRI = catheter-related infection; CRT = capillary refilling time; CSEP = clinical sepsis; CVC = central venous catheter; ECDC = European 
Centre for Disease Prevention and Control; LCBI = laboratory-confirmed bloodstream infection; NEC = necrotizing enterocolitis; NEO = neonatology; NHSN = National 
Healthcare Safety Network; PNEU = pneumonia; PPS = point prevalence survey; PVC = peripheral venous catheter; SYS = systemic infection 
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Supplementary table 2: Prevalence of children with one or more healthcare-associated infections – 
Paediatric data, ECDC point prevalence survey 2011-2012 
 
Country 
Healthcare-associated infections  
(N) 
Children  
(N)  
HAI prevalence 
*(95 % confidence interval) 
Poland 97 934 10.4 % (7.6-14.1) 
Finland 33 413 8.0 % (5.4-11.8) 
Cyprus 9 116 7.8 % (6.2-9.7) 
Iceland 3 39 7.7 % (3.7-15.3) 
Croatia 28 432 6.5 % (4.1-10.1) 
Netherlands 33 529 6.2 % (3.7-10.3) 
Estonia 6 100 6.0 % /(1.6-19.7) 
Greece 44 744 5.9 % (3.2-10.6) 
Spain 47 882 5.3 % (3.0-9.3) 
Luxemburg 3 63 4.8 % (1.7-12.6) 
Portugal 31 670 4.6 % (3.0-7.0) 
Belgium 42 936 4.5 % (2.5-7.9) 
United Kingdom 121 2857 4.2 % (3.2-5.6) 
Malta 3 71 4.2 % (4.1-4.4) 
Hungary 35 878 4.0 % (2.9-5.6) 
Norway 4 115 3.5 % (1.4-8.6) 
Denmark 1 30 3.3 % (1.0-10.7) 
Austria 7 210 3.3 % (1.1-10.0) 
Latvia 11 336 3.3 % (1.6-6.6) 
Bulgaria 37 1193 3.1 % (1.8-5.4) 
Slovenia 17 617 2.8 % (1.7-4.5) 
France 10 367 2.7 % (1.2-6.1) 
Ireland 21 801 2.6 % (1.7-4.1) 
Slovakia 28 1073 2.6 % (0.9-7.7) 
Lithuania 14 619 2.3 % (1.2-4.3) 
Italy 25 1166 2.1 % (1.5-3.2) 
Romania 8 471 1.7 % (0.6-5.1) 
Germany 4 280 1.4 % (0.2-8.6) 
Czech Republic 4 331 1.2 % (0.6-2.4) 
 
*95% confidence interval using two nested levels of clustering at the hospital level and country level; ECDC = 
European Centre for Disease Prevention and Control 
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Supplementary table 3: Predicted HAI prevalence among clinical settings and according to the number of children a hospital included in the survey – Paediatric data, 
standard protocol, ECDC point prevalence survey 2011-2012 
 
 Prevalence (%) 95%CI 
Clinical setting   
Paediatric intensive care 18.6  13.0-25.9 
Neonatal intensive care 12.6  10.6-14.9  
Neonatology 3.8  3.7-5.3  
Paediatric surgery 3.8  2.3-6.1  
General paediatrics 2.2  1.4-3.4  
 
95%CI: 95% confidence interval; ECDC: European Centre for Disease Prevention and Control; HAI: healthcare-associated infection 
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Supplementary table 4: Distribution of case-mix indicators compared to the number of children enrolled by the hospitals – Paediatric data, standard protocol, ECDC 
point prevalence survey 2011-2012 
 
 Number of children enrolled in the survey 
P-value 
≤25 26-40 41-70 >70 
McCabe classification 
Nonfatal 3846 (90.2%) 3287 (87.5%) 3586 (83.6%) 3159 (80.4%) <0.001 
Ultimately fatal 13 (0.3%) 22 (0.6%) 54 (1.3%) 24 (0.6%)  
Rapidly fatal 59 (1.4%) 70 (1.9%) 100 (2.3%) 158 (4.0%)  
Clinical setting 
Neonatal intensive care 258 (6.1%) 518 (13.8%) 704 (16.4%) 658 (16.8%) <0.001 
Paediatric intensive care 102 (2.5%) 148 (4.0%) 246 (5.7%) 268 (6.9%)  
General paediatrics 2760 (64.8%) 1915 (51.0%) 1632 (38.0%) 1549 (39.4%)  
Neonatology 1040 (24.4%) 1011 (26.9%) 1277 (29.8%) 853 (21.7%)  
Paediatric surgery 102 (2.4%) 166 (4.4%) 431 (10.1%) 599 (15.3%)  
Presence of an invasive medical device 
None 2548 (59.8%) 2247 (59.8%) 2323 (54.1%) 1976 (50.3%) <0.001 
1 device 1664 (39.0%) 1362 (36.2%) 1653 (38.5%) 1654 (42.1%)  
2 devices 39 (0.9%) 101 (27%) 215 (5.0%) 190 (4.8%)  
≥devices 11 (0.3%) 48 (1.3%) 99 (2.3%) 107 (2.7%)  
Length of stay (days)* 
<4 2135 (49.5%) 1703 45.3(%) 1869 (43.6%) 1430 (36.4%) <0.001 
4-7 1247 (28.9%) 1033 (27.5%) 1069 (24.9%) 1061 (27.0%)  
8-14 467 (10.8%) 471 (12.5%) 575 (13.4%) 604 (15.4%)  
>14 465 (10.8%) 551 (14.7%) 777 (18.1%) 832 (21.2%)  
 
*Before and including the day of the point prevalence survey  
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Supplementary table 5: Distribution of the major types of healthcare-associated infection, by country – 
Paediatric data, ECDC point prevalence survey 2011-2012 
 
Country 
HAI 
N 
BSI 
N (%) 
LCBI 
N (%) 
UTI 
N (%) 
SSI 
N (%) 
GI 
N (%) 
EENT 
N (%) 
OTH 
N (%) 
Austria 8 3 (37.5) 1 (12.5) 0 (0.0) 1 (12.5) 2 (25.0) 0 (0.0) 1 (12.5) 
Belgium 47 20 (42.6) 11 (23.4) 3 (6.4) 0 (0.0) 6 (12.8) 4 (8.5) 3(6.4) 
Bulgaria 39 8 (20.5) 18 (46.2) 3 (7.7) 0 (0.0) 2 (5.1) 5 (12.8) 3 (7.7) 
Croatia 28 13 (46.4) 8 (28.6) 3 (10.7) 1 (3.6) 3 (10.7) 0 (0.0) 0 (0.0) 
Cyprus 9 8 (88.9) 0 (0.0) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Czech Republic 4 1 (25.0) 0 (0.0) 0 (0.0) 2 (50.0) 1 (25.0) 0 (0.0) 0 (0.0) 
Denmark 1 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Estonia 6 5 (83.3) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Finland 34 20 (58.8) 2 (5.9) 0 (0.0) 1 (2.9) 3 (8.8) 3 (8.8) 5 (14.7) 
France 10 7 (70.0) 0 (0.0) 0 (0.0) 1 (10.0) 1 (10.0) 1 (10.0) 0 (0.0) 
Germany 4 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 
Greece 45 30 (66.7) 7 (15.6) 3 (6.7) 2 (4.4) 1 (2.2) 0 (0.0) 2 (4.4) 
Hungary 37 12 (32.4) 6 (16.2) 2 (5.4) 1 (2.7) 9 (24.3) 7 (18.9) 0 (0.0) 
Iceland 3 0 (0.0) 2 (66.7) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Ireland 22 16 (72.7) 1 (4.5) 0 (0.0) 1 (4.5) 3 (13.6) 0 (0.0) 1 (4.5) 
Italy 25 6 (24.0) 10 (40.0) 3 (12.0) 2 (8.0) 1 (4.0) 1 (4.0) 2 (8.0) 
Latvia 11 6 (54.5) 3 (27.3) 0 (0.0) 0 (0.0) 1 (9.1) 0 (0.0) 1 (9.1) 
Lithuania 14 2 (14.3) 11 (78.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) 0 (0.0) 
Luxembourg 3 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Malta 3 0 (0.0) 1 (33.3) 0 (0.0) 2 (66.7) 0 (0.0) 0 (0.0) 0 (0.0) 
Netherlands 35 11 (31.4) 2 (5.7) 0 (0.0) 1 (2.9) 1 (2.9) 3 (8.6) 17 (48.6) 
Norway 4 3 (75.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Poland 105 29 (27.6) 40 (38.1) 5 (4.8) 5 (4.8) 11 (10.5) 8 (7.6) 7(6.7) 
Portugal 35 16 (45.7) 3 (8.6) 1 (2.9) 2 (5.7) 2 (5.7) 3 (8.6) 8 (22.9) 
Romania 8 3 (37.5) 1 (12.5) 0 (0.0) 0 (0.0) 4 (50.0) 0 (0.0) 0 (0.0) 
Slovakia 31 9 (29.0) 7 (22.6) 2 (6.5) 0 (0.0) 1 (3.2) 11 (35.5) 1 (3.2) 
Slovenia 17 11 (64.7) 3 (17.6) 1 (5.9) 1 (5.9) 0 (0.0) 1 (5.9) 0 (0.0) 
Spain 56 31 (55.4) 6 (10.7) 8 (14.3) 4 (7.1) 4 (7.1) 1 (1.8) 2 (3.6) 
United Kingdom 126 69 (54.8) 25 (19.8) 2 (1.6) 5 (4.0) 7 (5.6) 6 (4.8) 12 (9.5) 
Total 770 343 (44.6) 171 (22.2) 37 (4.8) 34 (4.4) 64 (8.3) 55 (7.1) 121 (15.7) 
 
BSI: Bloodstream infection; EENT: Eye, ear, nose, throat infection; HAI: Healthcare-associated infection; GI: 
Gastrointestinal infection; LCBI: Lower respiratory tract infection; OTH: Other infection; SSI: Surgical site 
infection; UTI: Urinary tract infection 
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Supplementary figure 1: Distribution of the major types of healthcare-associated infection, by country – Paediatric data, ECDC point prevalence survey 2011-2012 
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Supplementary figure 2: Proportion of antimicrobial-resistant isolates for the major microorganisms documented in the survey (n=136) – Paediatric data, ECDC point 
prevalence survey 2011-2012 
 
 
